J Korean Med Sci.  2021 Dec;36(48):e328. 10.3346/jkms.2021.36.e328.

Evaluation of Three Multiplex Realtime Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs

• Yun J
• Park JH
• Kim N
• Roh EY
• Shin S
• Yoon JH
• Kim TS
• Hyunwoong H

• KMID: 2523306
• DOI: http://doi.org/10.3346/jkms.2021.36.e328

Abstract

Background
In the coronavirus disease 2019 (COVID-19) pandemic era, the simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (Flu), and respiratory syncytial virus (RSV) is important in the rapid differential diagnosis in patients with respiratory symptoms. Three multiplex real-time reverse transcription polymerase chain reaction (rRT-PCR) assays have been recently developed commercially in Korea: PowerChek™ SARS-CoV-2, Influenza A&B Multiplex Real-time PCR Kit (PowerChek; KogeneBiotech); STANDARD™ M Flu/SARS-CoV-2 Real-time Detection Kit (STANDARD M; SD BioSensor); and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay (Allplex; Seegene). We evaluated the analytical and clinical performances of these kits.
Methods
A limit of detection tests were performed and cross-reactivity analysis was executed using clinical respiratory samples. Ninety-seven SARS-CoV-2-positive, 201 SARS-CoV-2-negative, 71 influenza A-positive, 50 influenza B-positive, 78 RSV-positive, and 207 other respiratory virus-positive nasopharyngeal swabs were tested using the three assays. The AdvanSure™ respiratory viruses rRT-PCR assay (AdvanSure; LG Life Sciences) was used as a comparator assay for RSV.
Results
Except in influenza B, in SARS-CoV-2 and influenza A, there were no significant differences in detecting specific genes of the viruses among the three assays. All three kits did not cross-react with common respiratory viruses. All three kits had greater than 92% positive percent agreement and negative percent agreement and ≥ 0.95 kappa value in the detection of SARS-CoV-2 and flu A/B. Allplex detected RSV more sensitively than AdvanSure.
Conclusion
The overall performance of three multiplex rRT-PCR assays for the concurrent detection of SARS-CoV-2, influenza A/B, and RSV was comparable. These kits will promote prompt differential diagnosis of COVID-19, influenza, and RSV infection in the COVID-19 pandemic era.

Keyword

SARS-CoV-2; Influenza A Virus; Influenza B Virus; Respiratory Syncytial Viruses; Multiplex Polymerase Chain Reaction

Reference

1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(3):141–154. PMID: 33024307.

2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265–269. PMID: 32015508.

3. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021; 97(1147):312–320. PMID: 32978337.

4. So W. Age distribution of coronavirus (COVID-19) cases in South Korea as of October 8, 2021. Updated 2021. Accessed November 3, 2021. http://www.statista.com/statistics/1102730/south-korea-coronavirus-cases-by-age/ .

5. Turke PW. Five reasons COVID-19 is less severe in younger age-groups. Evol Med Public Health. 2021; 9(1):113–117. PMID: 34853694.

6. Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Physician. 2019; 100(12):751–758. PMID: 31845781.

7. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol. 2013; 45(3):331–379. PMID: 23575961.

8. Peteranderl C, Herold S, Schmoldt C. Human influenza virus infections. Semin Respir Crit Care Med. 2016; 37(4):487–500. PMID: 27486731.

9. Centers for Disease Control and Prevention. Key facts about influenza (Flu). Updated 2021. Accessed May 25, 2021. http://www.cdc.gov/flu/about/keyfacts.htm .

10. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV). Updated 2020. Accessed May 25, 2021. http://www.cdc.gov/rsv/clinical/index.html .

11. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018; 217(9):1356–1364. PMID: 29390105.

12. Ozaras R, Cirpin R, Duran A, Duman H, Arslan O, Bakcan Y, et al. Influenza and COVID-19 coinfection: report of six cases and review of the literature. J Med Virol. 2020; 92(11):2657–2665. PMID: 32497283.

13. Konala VM, Adapa S, Naramala S, Chenna A, Lamichhane S, Garlapati PR, et al. A case series of patients coinfected with influenza and COVID-19. J Investig Med High Impact Case Rep. 2020; 8:2324709620934674.

14. Tang ML, Li YQ, Chen X, Lin H, Jiang ZC, Gu DL, et al. Co-Infection with common respiratory pathogens and SARS-CoV-2 in patients with COVID-19 pneumonia and laboratory biochemistry findings: a retrospective cross-sectional study of 78 patients from a single center in China. Med Sci Monit. 2021; 27:e929783. PMID: 33388738.

15. Nature. The coronavirus is here to stay — here’s what that means. Updated 2021. Accessed June 2, 2021. http://www.nature.com/articles/d41586-021-00396-2 .

16. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020; 20(5):453–454. PMID: 32297805.

17. Hur KH, Park K, Lim Y, Jeong YS, Sung H, Kim MN. Evaluation of four commercial kits for SARS-CoV-2 real-time reverse-transcription polymerase chain reaction approved by Emergency-Use-Authorization in Korea. Front Med (Lausanne). 2020; 7:521. PMID: 32903503.

18. Zhen W, Smith E, Manji R, Schron D, Berry GJ. Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2. J Clin Microbiol. 2020; 58(8):e00783–e00720. PMID: 32332061.

19. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. Euro Surveill. 2020; 25(9):2000152.

20. U.S. Food and Drug Administration. In vitro diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2. Updated 2021. Accessed May 25, 2021. http://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular .

21. World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: Interim guidance, 19 March 2020. Updated 2020. Accessed May 25, 2021. http://apps.who.int/iris/handle/10665/331501 .

22. Jung YJ, Kwon HJ, Huh HJ, Ki CS, Lee NY, Kim JW. Comparison of the AdvanSure™ real-time RT-PCR and Seeplex (®) RV12 ACE assay for the detection of respiratory viruses. J Virol Methods. 2015; 224(2):42–46. PMID: 26277911.

23. Nörz D, Hoffmann A, Aepfelbacher M, Pfefferle S, Lütgehetmann M. Clinical evaluation of a fully automated, laboratory-developed multiplex RT-PCR assay integrating dual-target SARS-CoV-2 and influenza A/B detection on a high-throughput platform. J Med Microbiol. 2021; 70(2):001295.

24. Leung EC, Chow VC, Lee MK, Tang KP, Li DK, Lai RW. Evaluation of the Xpert Xpress SARS-CoV-2/Flu/RSV assay for simultaneous detection of SARS-CoV-2, influenza A/B and respiratory syncytial viruses in nasopharyngeal specimens. J Clin Microbiol. 2021; 59(4):e02965–e02920. PMID: 33436456.

25. Korea Disease Control and Prevention Agency. Pathogens & Vector Surveillance Weekly Report, PVSWR 2019. 10. 6.–10. 19. Updated 2019. Accessed November 7, 2021. http://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=3&pblctDtaSn=1988 .

26. Korea Disease Control and Prevention Agency. Pathogens & Vector Surveillance Weekly Report, PVSWR 2021. 8. 29.–2021. 9. 11. Updated 2021. Accessed November 7, 2021. http://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=3&pblctDtaSn=2443 .

27. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020; 323(20):2085–2086. PMID: 32293646.

28. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol. 2020; 92(11):2870–2873. PMID: 32530499.

29. Kim YG, Park H, Kim SY, Hong KH, Kim MJ, Lee JS, et al. Rates of coinfection between SARS-CoV-2 and other respiratory viruses in Korea. Ann Lab Med. 2022; 42(1):110–112. PMID: 34374357.